3889. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial.
作者: Patricia Pozo-Rosich.;Jessica Ailani.;Messoud Ashina.;Peter J Goadsby.;Richard B Lipton.;Uwe Reuter.;Hua Guo.;Brittany Schwefel.;Kaifeng Lu.;Ramesh Boinpally.;Rosa Miceli.;Rosa De Abreu Ferreira.;Emily McCusker.;Sung Yun Yu.;Lawrence Severt.;Michelle Finnegan.;Joel M Trugman.
来源: Lancet. 2023年402卷10404期775-785页
In this study, we aimed to evaluate the efficacy, safety, and tolerability of atogepant for the preventive treatment of chronic migraine.
3891. Advancing integrated governance for health through national biodiversity strategies and action plans.
作者: Liz Willetts.;Carly Siege.;Anna M Stewart-Ibarra.;Ojistoh Horn.;Benjamas Chotthong.;Tanirat Tanawat.;Phyllis Omido.;Manushi Sharma.;Lujain Alqodmani.;Nathan J Bennett.;Christopher D Golden.;Cicilia Wangari Githaiga.;Neil M Vora.
来源: Lancet. 2023年402卷10404期753-756页 3892. Cutaneous melanoma.
作者: Georgina V Long.;Susan M Swetter.;Alexander M Menzies.;Jeffrey E Gershenwald.;Richard A Scolyer.
来源: Lancet. 2023年402卷10400期485-502页
Cutaneous melanoma is a malignancy arising from melanocytes of the skin. Incidence rates are rising, particularly in White populations. Cutaneous melanoma is typically driven by exposure to ultraviolet radiation from natural sunlight and indoor tanning, although there are several subtypes that are not related to ultraviolet radiation exposure. Primary melanomas are often darkly pigmented, but can be amelanotic, with diagnosis based on a combination of clinical and histopathological findings. Primary melanoma is treated with wide excision, with margins determined by tumour thickness. Further treatment depends on the disease stage (following histopathological examination and, where appropriate, sentinel lymph node biopsy) and can include surgery, checkpoint immunotherapy, targeted therapy, or radiotherapy. Systemic drug therapies are recommended as an adjunct to surgery in patients with resectable locoregional metastases and are the mainstay of treatment in advanced melanoma. Management of advanced melanoma is complex, particularly in those with cerebral metastasis. Multidisciplinary care is essential. Systemic drug therapies, particularly immune checkpoint inhibitors, have substantially increased melanoma survival following a series of landmark approvals from 2011 onward.
3893. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
作者: Shukui Qin.;Stephen L Chan.;Shanzhi Gu.;Yuxian Bai.;Zhenggang Ren.;Xiaoyan Lin.;Zhendong Chen.;Weidong Jia.;Yongdong Jin.;Yabing Guo.;Xiaohua Hu.;Zhiqiang Meng.;Jun Liang.;Ying Cheng.;Jianping Xiong.;Hong Ren.;Fang Yang.;Wei Li.;Yajin Chen.;Yong Zeng.;Alexander Sultanbaev.;Monika Pazgan-Simon.;Margaryta Pisetska.;Davide Melisi.;Dmitriy Ponomarenko.;Yurii Osypchuk.;Ivan Sinielnikov.;Tsai-Sheng Yang.;Xiao Liang.;Chunxia Chen.;Linna Wang.;Ann-Lii Cheng.;Ahmed Kaseb.;Arndt Vogel.; .
来源: Lancet. 2023年402卷10408期1133-1146页
Immunotherapy with immune checkpoint inhibitors combined with an anti-angiogenic tyrosine-kinase inhibitor (TKI) has been shown to improve overall survival versus anti-angiogenic therapy alone in advanced solid tumours, but not in hepatocellular carcinoma. Therefore, a clinical study was conducted to compare the efficacy and safety of the anti-PD-1 antibody camrelizumab plus the VEGFR2-targeted TKI rivoceranib (also known as apatinib) versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma.
3895. The risk of sexual transmission of HIV in individuals with low-level HIV viraemia: a systematic review.
The risk of sexual transmission of HIV from individuals with low-level HIV viraemia receiving antiretroviral therapy (ART) has important public health implications, especially in resource-limited settings that use alternatives to plasma-based viral load testing. This Article summarises the evidence related to sexual transmission of HIV at varying HIV viral load levels to inform messaging for people living with HIV, their partners, their health-care providers, and the wider public.
|